OPTN (Option Therapeutics) Equity-to-Asset: 0.99 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Option Therapeutics Equity-to-Asset?

Option Therapeutics OPTN Equity-to-Asset is 0.99 as of Dec. 2025.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Option Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $1.20 Mil. Option Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was $1.21 Mil.

The historical rank and industry rank for Option Therapeutics's Equity-to-Asset or its related term are showing as below:

OPTN's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Equity-to-Asset only.

Option Therapeutics  (AMEX:OPTN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Option Therapeutics Equity-to-Asset Related Terms

Option Therapeutics Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for Option Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Option Therapeutics Equity-to-Asset Chart

Option Therapeutics Annual Data
Trend Jun24 Jun25
Equity-to-Asset
0.98 0.88

Option Therapeutics Quarterly Data
Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Equity-to-Asset Get a 7-Day Free Trial 0.00 0.00 0.88 0.99 0.99

OPTN vs : Equity-to-Asset Comparison

For the Biotechnology subindustry, Option Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Option Therapeutics Equity-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Option Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Option Therapeutics's Equity-to-Asset falls into.


Option Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Option Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Equity to Asset (A: Jun. 2025 )=Total Stockholders Equity/Total Assets
=0.89/1.017
=

Option Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

Equity to Asset (Q: Dec. 2025 )=Total Stockholders Equity/Total Assets
=1.196/1.206
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of 0.99 mean?
Option Therapeutics (OPTN) has a Equity-to-Asset of 0.99 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Option Therapeutics and its competitors.
Is Option Therapeutics' Equity-to-Asset too high?
Option Therapeutics' current Equity-to-Asset is 0.99. The Biotechnology industry median Equity-to-Asset is 0.68. Option Therapeutics' value of 0.99 is 45.6% above this industry median.
How does Option Therapeutics' Equity-to-Asset compare to ?
Option Therapeutics' Equity-to-Asset of 0.99 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.68. Option Therapeutics' value of 0.99 is 45.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Option Therapeutics's current Equity-to-Asset of 0.99 is 45.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Option Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Option Therapeutics's current Equity-to-Asset is 0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Option Therapeutics stock overvalued right now?
Option Therapeutics (OPTN) has a current Equity-to-Asset of 0.99. The current Equity-to-Asset is 0.99 and 45.6% above the Biotechnology industry median of 0.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Option Therapeutics (OPTN), the current Equity-to-Asset is 0.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Option Therapeutics Business Description

Comparable Companies
Address 680 West Nye Lane, Suite 201, Carson, NV, USA, 89703
Option Therapeutics Inc is a clinical-stage company developing inventive drug therapies to treat debilitating and life-threatening liver disease through its investigational drug candidate BIV201 (continuous infusion terlipressin). BIV201 is administered as a patent-pending liquid formulation of terlipressin with patents issued, to date, in the U.S., China, Japan, Chile, and India.